医学
奥西默替尼
肺癌
佐剂
外科切除术
肿瘤科
外科
内科学
癌症
腺癌
ROS1型
作者
Muhammad Awidi,Angel Mier-Hicks,Stuthi Perimbeti,Kristopher Attwood,Hongbin Chen,Prantesh Jain,Edwin Yau,Amy Early,Grace K. Dy
标识
DOI:10.1016/j.cllc.2024.05.003
摘要
The ADAURA trial confirmed adjuvant Osimertinib's efficacy in EGFR-mutated Non-small-cell lung cancer (NSCLC), yet the limited mature overall survival (OS) data at approval poses a challenge. This study explores patient preferences in the absence of complete OS information, hypothesizing that disease-free survival (DFS) benefit alone may influence adjuvant Osimertinib pursuit.
科研通智能强力驱动
Strongly Powered by AbleSci AI